In this issue: Fatigue. It’s one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient’s life. What can clinicians do to better identify MS fatigue? And what do they need to know t

In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity a

Hosted on Acast. See acast.com/privacy for more information.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT agai

Whats the evidence supporting the existence of an MS prodromal phase where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosin

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections

Too many individuals with MS are not receiving access to the most effective care. Why? Whats behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan K

How burdensome is spasticity for patients with MS? Whats the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?  These are the key questions Program Director Dr. Michael

In her Expert Commentary, Dr. Melanie Ward from West Virginia Universitys Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of

How aware are clinicians that MS should no longer be considered a White people only disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provi